Clover Biopharmaceuticals, Ltd.
三葉草生物製藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2197)

VOLUNTARY ANNOUNCEMENT
CLOVER ANNOUNCES ADDITIONAL POSITIVE U.S. PHASE I CLINICAL DATA FOR RSV RE-VACCINATION IN OLDER ADULTS

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Clover Biopharmaceuticals, Ltd. (the "**Company**" or "**Clover**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company and potential investors on the latest business development of the Group.

The Company is pleased to announce additional positive data from a Phase I clinical trial in the U.S. evaluating re-vaccination with the Company's RSV PreF vaccine candidate (SCB-1019) compared head-to-head versus GSK's RSV vaccine (AREXVY) in older adults (60-85 years) that previously received AREXVY at least 2 seasons prior to enrolling. Participants were randomized to receive either a heterologous SCB-1019 (Clover RSV PreF) revaccination dose, a homologous AREXVY (GSK RSV PreF) revaccination dose or saline placebo. The study is assessing safety, reactogenicity and immunogenicity. The results announced today are from 62 participants, whereas the results announced in October 2025 were from 34 participants.

An analysis for immunogenicity in all enrolled participants has been performed. Preliminary and exploratory results from 62 participants (30 participants receiving SCB-1019, 26 participants receiving AREXVY, 6 participants receiving saline placebo) are summarized below:

- SCB-1019 heterologous re-vaccination induced an approximately 60-80% higher trend in RSV-A and RSV-B nAb (neutralizing Antibody) geometric mean titers (GMTs) compared to AREXVY homologous re-vaccination; no significant changes in RSV nAbs were observed for the placebo group;

- An exploratory cross-trial comparison to sera from Clover's prior clinical study in RSV vaccine-naïve older adults receiving an initial dose of AREXVY suggests that SCB-1019 heterologous re-vaccination restores RSV-A and RSV-B nAb GMTs to approximately 120-135% of peak levels observed following an initial dose of AREXVY, whereas AREXVY heterologous re-vaccination restored GMTs to only approximately 75% of peak levels;

- AREXVY homologous re-vaccination induced an approximately 40-fold increase in "off-target" antibodies against the T4-foldon trimerization tag utilized in AREXVY.

Given that more than 40% of eligible adults 60 years and older in the U.S. have previously received an protein-based RSV vaccine (comprising approximately 15 million doses)[1], and clinical data to-date for currently approved RSV vaccines have not supported RSV re-vaccination policy recommendations despite waning efficacy observed

after the initial dose, Clover's clinical data to-date suggest the potential for Clover's RSV+hMPV±PIV3 combination vaccine candidates to both restore protection against RSV and broaden protection to hMPV±PIV3 in this population.

Clover's RSV+hMPV±PIV3 combination vaccine candidates are currently being evaluated in an ongoing Phase II clinical trial that initiated enrollment in January 2026.

Note:

1. U.S. CDC Weekly RSV Vaccination Dashboard (data as of April-May 2025).

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Clover Biopharmaceuticals, Ltd.
Dr. Peng LIANG
Chairman of the Board

Shanghai, PRC, March 25, 2026

As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG and Dr. Donna Marie AMBROSINO as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.